Table 2. Sensitivity and specificity of tests according to present study.
| Test, manufacturera | Antibody class and protein | Sensitivityb | Specificityc |
|---|---|---|---|
| MAGLUMI 2019-nCoV IgG, SNIBE (Shenzhen New Industries Biomedical Engineering Co) | IgG, not specified | 70.1% | 98% |
| SARS-CoV-2 ELISA IgG, EUROIMMUN AG | IgG, S1 | 82.5% | 98% |
| SARS-CoV-2 IgG, Abbott Laboratories | IgG, N | 84.5% | 100% |
| Elecsys® Anti-SARS-CoV-2, Roche Diagnostics GmbH | Total Ab, N | 83.5% | 100% |
| EDI™ Novel Coronavirus COVID-19 IgG ELISA, Epitope Diagnostics Inc | IgG, N and S | 85.6% | 98% |
| LIAISON® SARS-CoV-2 S1/S2 IgG, DiaSorin S.p.A. | IgG, S1 and S2 | 81.4% | 99% |
| STANDARDTM Q COVID-19 IgM/IgG Duo Test, SD Biosensor Inc | IgG, N | 64.9% | 100% |
| LIPS S-RBD IgG, in-house | IgG, S-RBD | 84.5%d | 98%d |
| LIPS N IgG, in-house | IgG, N | 91.8%d | 98%d |
aShort names used in the text are indicated in bold.
bBased on testing of 97 serum samples from COVID-19 patients’ in present study.
cBased on testing of 100 pre COVID-19 sera in present study.
dIn LIPS tests statistical (not clinically validated) cut-offs were applied.